Jim Cramer Recommends Eli Lilly Over Viking Therapeutics

Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the stocks Jim Cramer was asked about. Mentioning that they are a long-term shareholder of VKTX, a caller said that they have been observing the bidding war between Novo Nordisk and Pfizer for Metsera. Cramer commented:

“Yeah, I know, and I’ve watched that, and I don’t, I think that Viking would’ve gotten a bid if it didn’t get it yet. I know people are expecting whoever loses in that war that you just mentioned is going to buy Viking. I tell you what, you should buy. You own Eli Lilly. That’s been the winner. The trust owns it. I really like it a lot.”

Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage biopharmaceutical company developing therapies for metabolic and endocrine disorders. During the lightning round of September 4, a caller asked about the stock, and Cramer said:

“No, no, no. We have Eli Lilly. Why do we have to settle? Let’s, don’t, don’t go for the raggedy rest. Let’s go for the best.”

While we acknowledge the potential of VKTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.